Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
What is the purpose of this trial?
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance the effect of radiotherapy, and this study will seek to confirm this.
- 18 Years - N/A
- Merck Sharp & Dohme Corp.
- May 2009
- Last Updated:
- December 7, 2012
- Study HIC#:
Clinicaltrials.gov ID: NCT00821951